A social network for physicians: MSD France’s “Comuniti” win the ‘Most Valuable HCP or Healthcare Initiative’ at eyeforpharma Barcelona Awards 2016.

Think Facebook for physicians; MSD France stood out from the crowd by defying the odds to launch the first social network for physicians in France. The secret to launching a social network is a black box that has beaten the best of Silicon Valley, speaking to the significance of the achievement for those behind the Comuniti platform.

The project was conceived to meet growing demands for better communication and collaboration between the HCP community. The goal was to help members save time and improve their practice through creating access to the expertise of others. This led to the design and inclusion of additional features to help collaboration, beyond just instant messaging, including videoconferencing and document sharing.

Early user engagement is evidence that MSD France have correctly identified an unmet need. Just 6-months after a multichannel launch, that included ad placement across radio, Facebook, banner placements and email marketing, they’ve hit 65,000 registered users. The team now have ambitions to scale out globally.

The winning projects were selected from hundreds of initiatives from Europe, Middle East, Africa and Asia/Pac, and announced yesterday at the 3rd annual eyeforpharma Barcelona Awards ceremony, determined by an international judging panel of senior industry experts, and patient advocates.

The ‘Most Valuable HCP or Healthcare Initiative’, previously won by Janssen Healthcare Innovation and the George Institute for Global Health, is designed to celebrate innovation that improves healthcare delivery both in the long and short term.

This award category, and others, reflects eyeforpharma’s mission to evangelize the need for pharma to change its focus from selling products, to seeing the powerful opportunity that pharma has to impact and improve the lives of patients.

For more information, contact: Emma Goldman, Awards Director egoldman@eyeforpharma.com +44 (0) 207 375 4312

comments powered by Disqus